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ABSTRACT
In this study, we analyzed the human immunodeficiency type 1 (HIV-1) viruses circulating between 1999 and
2004 in antiretroviral-naive women from a rural area of southern Mozambique. Nucleotide sequencing of the
HIV-1 long terminal repeat (LTR) U3, envelope (env) C2V3C3, and protease (pr) genomic regions was per-
formed from women sera samples collected in 1999 and 2004. Phylogenetic analysis revealed that all ampli-
fied sequences belonged to subtype C. Although env sequences were predominantly CCR5-tropic (R5), CXCR4-
tropic (X4) variants were also identified (13%). Both 1999 and 2004 sequences were widely dispersed across
multiple clusters and were related to different reference sequences from neighboring countries. Sequences
from 2004 showed significantly more nucleotide genetic diversity than sequences from 1999. Importantly, ge-
netic diversification was also observed at the pr and env amino acid level, suggesting that positive selection
forces were implicated in the viral diversification. These results indicate the rapid spread and diversification




SUB-SAHARAN AFRICA is the region most severely affected byHIV-1, with 24.7 million (60%) of the 39.5 million people
living with HIV/AIDS.1 This region is characterized by the cir-
culation of several genotypes and circulating recombinant forms
(CRFs).2 However, subtype C viruses are rapidly spreading in
southern Africa and becoming the predominant variant of the
epidemic, accounting for more than 56% of all global infec-
tions.3,4 There is evidence that suggests that different subtypes
may have distinct biological features that may have an impact
on transmissibility and on disease progression.5,6 The high ge-
netic variability of HIV-1 and its potential for recombination
are clearly important to escape from the immune system and
also play a major role in the development of resistance to highly
active antiretroviral therapy (HAART).7,8
There has been tremendous development of new antiretro-
viral drugs for the treatment of HIV-1 subtype B viruses, but
information on their efficacy in nonsubtype B viruses is scarce.
Recently, the genetic characterization of the protease and re-
verse transcriptase genes from non-B subtypes has revealed that
minor mutations are often present in natural variants.9–11 How-
ever, it is unknown whether the presence of these polymor-
phisms facilitates the generation of resistance during treatment
with protease inhibitors (PI).12
Although Mozambique is ranked as having the tenth highest
HIV-1 prevalence in the world, relatively little information on
the molecular epidemiology of HIV-1 in Mozambique is avail-
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able. Mozambique suffered a long civil war until 1992, and
since then, the spread of HIV-1 has been increasing rapidly,
with a shift in overall reported prevalence from 8.2% in 1998
to 16.2% in 2004.13 The number of people living with HIV-1
is estimated to be approximately 1.8 (1.4–2.2) million, with
women representing up to 58% of those infected.1 In Mozam-
bique, it is estimated that only 3.4% of pregnant women who
need antiretroviral therapy (ART) for prevention of mother-to-
child transmission actually receive it. Furthermore, of those
HIV-1-infected adults in Mozambique who require HAART,
only approximately 9% receive treatment.1
To date, there are only two published studies assessing both
HIV-1 subtypes and genetic diversity in Mozambique. One
study evaluated drug resistance in drug-naive HIV-1 patients in
two hospitals near Maputo.14 The second study performed ge-
netic characterization of HIV-1 circulating in Beira, a central
region of the country.15 Both studies determined that subtype
C was the dominant HIV-1 subtype. However, in Mozambique
longitudinal studies analyzing HIV-1 genetic diversification
and evolution are lacking. Large-scale implementation of
HAART has begun in many southern and eastern African coun-
tries, including Mozambique. Therefore, studies including phy-
logenetic analysis, drug resistance polymorphisms, genetic di-
versity, and molecular evolution of HIV-1 may improve the
treatment success in this area.
To gain a better understanding of genetic diversity, molecu-
lar evolution and epidemiological patterns of HIV-1 spread, and
drug resistance polymorphisms, we studied regions in the HIV
U3 long terminal repeat (LTR), the envelope (env) C2V3C3
and protease (pr) gene. This study focused on HIV-1 sequences
obtained in 1999 and in 2004, from women living in a semi-
rural area of southern Mozambique.
MATERIALS AND METHODS
Study area and population
The study was undertaken at the Centro de Investigação em
Saúde da Manhiça (CISM) in Manhiça District, southern
Mozambique. Blood samples were obtained from HIV-positive
women at the time of recruitment from two different studies
performed in 1999 and 2004.16,17 After obtaining written in-
formed consent, blood samples were collected in EDTA anti-
coagulant tubes and plasma was stored at 80°C until analyzed.
HIV-1 disease status was not available for these women. Since
HAART was not available in Manhiça during these studies, all
women were considered to be drug naive at recruitment. The
1999 study included 300 women, of whom 30 were HIV, aged
14–61 years and attending antenatal and family planning clin-
ics. The 2004 study included 1030 pregnant women attending
the antenatal clinic of whom 207 were HIV. Both studies were
approved by the Ethics Review Board of Mozambique and Hos-
pital Clinic of Barcelona.
PCR amplification and sequencing
Extraction of viral RNA from the 1999 plasma samples was
performed using the Qiamp viral RNA mini kit (Qiagen) and
viral load was determined using the Cobas Amplicor HIV-1
Monitor Test v1.5 (Roche Diagnostics). For the 2004 samples,
viral load was determined using the Amplicor HIV-1 Monitor
Test v1.5 (Roche Diagnostics) and due to the small volume of
samples, RNA extracted during this process was reverse tran-
scribed to cDNA with Superscript II and random hexamer
primers (Invitrogen). The RNA template and random primers
(300 ng) were heated to 65°C for 10 min, chilled on ice, and
reverse transcribed in a 20 l reaction volume containing 1
reaction buffer, 109 mM dithiothreitol, 0.5 mM each deoxynu-
cleoside triphosphate, and 200 U of Superscript reverse tran-
scriptase (Invitrogen) at 37°C for 1 h, followed by 15 min at
95°C. The cDNA was shipped to Fundació Irsi-Caixa
(Barcelona, Spain) where amplification and sequencing were
performed.
Amplification of the U3 LTR, env C2V3C3 region, and pr
was performed for the 1999 and 2004 samples. The LTR and
env C2V3C3 regions were amplified following the reaction con-
ditions and primers described in Ibanez et al. and Tapia et al.,
respectively.18,19 LTR primers used for first-round amplifica-
tion were NI25 (HXB2 positions 57–77) and NI23 (HXB2 po-
sitions 389–408) and for second-round amplification were NI33
(HXB2 positions 350–372) and NI35 (HXB2 positions
81–100). The outer pair of primers for env amplification were
ENV1 (HXB2 positions 6858–6878) and ENV4 (HXB2 posi-
tions 7520–7539) and the inner primers were ENV2 (HXB2 po-
sitions 6885–6904) and ENV3 (HXB2 positions 7365–7385).
The pr region was amplified from the cDNA with 5PROT1 (5-
ATTTTTTA GGGAARATYTGGCCT-3; positions 2084–
2106) and 3PROT1 (5-YTGGAGTR TTRTATGGATTTT-
CAGG-3; positions 2703–2727) as outer primers and 5PROT2
(5-ATTTTTTAGGGAARATYTGGCCT-3; positions 2118–
2140) and 3PROT2 (5-CTTTTATTTTYTCTTCTGTYAA-
TGG-3; positions 2622–2646) as inner primers. The following
amplification conditions were used for the first-round and
nested polymerase chain reaction (PCR): 2 min at 95°C, fol-
lowed by 35 cycles of 30 s at 95°C, 30 s at 55°C, 40 s at 72°C,
and a final extension step at 72°C for 7 min.
Both strands of the PCR fragments were purified with Exo-
SAP-IT (Applied Biosystems) and sequenced directly using in-
ternal (nested) PCR primers and the ABI Prism Dye Termina-
tor Cycle Sequencing Reaction kit (Perkin Elmer). The products
of the reactions were then analyzed on an ABIprism 3100 se-
quencer (Perkin Elmer). Sequence editing was performed us-
ing the program SEQUENCHER, version 4.6 (GeneCodes).
Subtyping and phylogenetic analysis
The new sequences were manually edited with BioEdit ver-
sion 7 and compared to subtype reference strains downloaded
from the Los Alamos subtype database (http://hiv-web.lanl.
gov/content/hiv-db/SUBTYPE_REF/align.html). To examine
intrasubtype variations, a subset of subtype C from neighbor-
ing countries was downloaded from the Los Alamos BLAST
search database (http://hiv-web.lanl.gov). Multiple alignments
were performed with Clustal W 1.7.20 Sequence and phyloge-
netic analyses were performed as previously described.21,22
Briefly, phylogenetic trees were created with PAUP* version
4.0b 10 with likelihood settings by selecting the best-fitting evo-
lutionary models with the Akaike identification system, imple-
mented in Modeltest 3.6.23,24 The TVMIG model was used
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for LTR, the GTRIG model for the protease region, and the
K81ufIG for the envelope region. The robustness of the
trees was evaluated by bootstrap analysis with 1000 rounds of
replication. Trees were viewed with Treeview.25 The sequence
ID used to name the study sequences is the ID number used in
the CISM to track samples, while the sequence ID for the 
reference strains has been simplified with the initials of the
country.
Mean genetic distances were measured with the corre-
sponding model for each region implemented in PAUP* ver-
sion 4.0b.23 SNAP (http://hiv-web.lanl.gov) was used to 
calculate the synonymous-to-nonsynonymous substitution
ratio.26,27 The V3 loop amino acid sequences were intro-
duced into the WebPSSM program (http://ubik.microbiol.
washington.edu/ computing/pssm) to determine the corecep-
tor usage and the net charge of the V3 loop.28–30 The V3
loop of the virion’s envelope glycoprotein gp120 has been
identified as a major determinant for viral tropism and core-
ceptor usage, depending on its net charge and the polarity of
the amino acids located at positions 11 and 25.31 A lower
V3 net charge facilitates a tighter interaction of gp120 with
CCR5 while a higher V3 net charge facilitates the interac-
tion with CXCR4.32
Drug resistance genotyping
The Stanford University HIV Drug Resistance database (aIg
Program) (http://hivdb.stanford.edu) was used to determine re-
sistance-associated mutations and polymorphisms present in the
protease (1999 and 2004 sequences). Known mutations and/or
polymorphisms were assessed in the protease sequences from
1999 (n  20) and from 2004 (n  31).
Statistical analyses
The nonparametric Mann–Whitney test was used to test for
differences between intrasubtype genetic distances, synony-
mous and nonsynonymous mutations, and distance to ancestor
between 1999 and 2004 sequences. A p value lower than 0.05
was considered statistically significant. Analyses were per-
formed using the Graph Pad software package, version 4
(GraphPad Software, Inc.).
RESULTS
Characteristics of the study population
Manhiça district, a semirural area of southern Mozambique,
has an estimated population of 36,000 inhabitants under 
demographic surveillance prior to 2004. The prevalence of 
HIV-1 infection in pregnant women attending the antenatal
clinic was 12% in 1999 and 23% in 2004.16,17 Both in 1999
and 2004, the two populations were women, with a median age
of 33 (IQR 25–48) and 23 (IQR 20–30) years, respectively. All
women from the 2004 study and 60% of women from the 1999
study were pregnant at the time of sample collection. The two
groups had similar viral load levels, with median values of
12,200 copies/ml (IQR 3650–36,100) for the 1999 study pop-
ulation and 18,620 (IQR 10,388–49,091) copies/ml for the 2004
study population (p  0.11).
Subtyping and phylogenetic analysis
To subtype and determine the phylogenetic relationships be-
tween sequences, the LTR, env, and pr regions were amplified
from available sera samples collected in 1999 and 2004. Of the
30 HIV blood samples available from 1999, amplification was
successfully performed for LTR (n  21), env (n  18), and pr
(n  20). Of the 207 HIV women in the 2004 study, 51 were
randomly chosen for this study. Due to small quantities of cDNA,
out of the 51 samples available from 2004, amplification was per-
formed for LTR (n  37), env (n  32), and pr (n  31).
Phylogenetic analysis showed that all sequences from LTR, env,
and pr clustered into the subtype C clade (data not shown). To in-
vestigate within-subtype C clustering, phylogenetic trees were con-
structed with published LTR, envelope, and protease C sequences
from central Mozambique and several sequences from nine dif-
ferent African neighboring countries (South Africa, Zimbabwe,
Tanzania, Malawi, Ethiopia, Kenya, Botswana, Somalia, and Sene-
gal) from the sequences available at the Los Alamos HIV sequence
database (http://www.hiv.lanl. gov/components/hiv-db/combined_
search_s_tree/search.html).
Both 1999 and 2004 envelope sequences from Manhiça were
widely dispersed across multiple clusters (Fig. 1A). Similar tree
topologies were obtained for LTR and protease (Fig. 1B and
C), although the envelope tree tended to have higher bootstrap
values reflecting a higher robustness of the clusters.
Different phylogenetic associations were observed with other
subtype C sequences from neighboring countries. However, dis-
tance matrix-based phylogenetic analysis did not reveal poten-
tial clusters and couples of genetically related sequences (boot-
strap values higher than 70%) between our sequences and any
of the reference sequences from neighboring countries. Distinct
sublineages consisting only of closely related Mozambican se-
quences from 1999 and 2004 with bootstrap values higher than
70% were identified in LTR, envelope, and protease, suggest-
ing an epidemiological link between these samples (marked
with brackets in Fig 1).
Genetic divergence and selection pressure
To assess the intrasubtype genetic diversity, the genetic dis-
tances between each set of sequences were calculated. Signifi-
cantly higher median genetic distances were observed for se-
quences from 2004 as compared to sequences from 1999 in all
regions assessed: LTR, env, and pr (Table 1). Larger median
genetic distances reflecting increased genetic diversity were
most pronounced in the envelope region.
Sequences were compared to assess the mutational pattern
of protease and envelope in the absence of drug therapy (Table
1). Both genes were found to be under purifying (negative) se-
lection pressure with a ratio of ds/dn greater than 1. The aver-
age ds/dn for both 1999 and 2004 sequences was 1.979 and
2.047 for the envelope region and 6.123 and 7.196 for the pro-
tease region, respectively. Protease showed very low rates of
nonsynonymous mutations reflecting different pressure con-
straints between pr and env genes.
Coreceptor usage determined by V3 loop sequences
The average net charge in this group of sequences was 4.3.
The characteristic GPGQ crown found in most non-B subtypes



































































































FIG. 1. (A) Envelope sequences from Manhiça (both 1999 and 2004) were widely dispersed across multiple clusters. Similar
































































































































































































was conserved in 98% (49/50) of the samples. According to the
sequence analysis with WebPSSM, 88% (44/50) of the viruses
potentially used CCR5, with six sequences reflecting potential
R5X4 or X4 receptor usage (three from 1999 and three from
2004). Although these results indicated a predominance of R5
viruses, they also showed that potential X4 receptor usage is
not prohibited in subtype C envelope regions.
Mutations associated with drug resistance to 
protease inhibitors
No primary resistance mutations to protease inhibitors were
detected in any of the 51 samples. However, a high prevalence
of minor mutations was observed at the following positions:
K20R (21.6%), M36I (74.5%), L63P (27.5%), and I93L
(94.1%). Other polymorphisms present at lower frequency are
reported in Table 2.
DISCUSSION
Despite the high prevalence of HIV-1 in Mozambique, so far
only two studies have examined the genetic diversity of
Mozambican HIV-1 viruses.14,15 Thus, the aim of this study
was to characterize the HIV-1 epidemic at a molecular level in
women from a rural area of southern Mozambique and to as-
sess viral genetic diversity in 1999 and in 2004.
Subtype analysis showed that all the LTR, envelope, and pro-
tease regions studied were subtype C, in accordance with other
studies that found all HIV-1 isolates in Maputo, Mozambique
to be subtype C and all but one to be subtype C in Beira.14,15
Overall, these results indicate that the HIV-1 epidemic in
Mozambique is quite homogeneous with regard to subtype since
it is composed almost exclusively of clade C viruses. This is
similar to the situation found in neighboring countries such as
South Africa, but different from countries such as Tanzania that
also have A and D viruses circulating.19,33 Phylogenetic analy-
ses revealed that Mozambican sequences did not form a coun-
try-specific cluster. Instead, sequences were randomly spread
throughout the trees without showing different homology from
other subtype C sequences from neighboring countries. The
wide genetic variation of these sequences suggests multiple in-
troductions of subtype C viruses in Mozambique and thus con-
firms the existence of multiple circulating clade C sublineages
in southern Africa as described.34 Studies of population migra-
tions suggest that HIV-1 introduction into Mozambique may
have been associated with the frequent temporary labor migra-
tions of adult males from southern Mozambique to South
Africa.35
Nucleotide substitutions in genes coding for proteins can be
either synonymous (no change of amino acid) or nonsynony-
mous (change of amino acid). Investigating the number of syn-
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TABLE 1. GENETIC DISTANCES, RATIO OF NONSYNONYMOUS TO SYNONYMOUS AMINO ACID SUBSTITUTIONS
1999 sequencesa 2004 sequencesb
Median SD Median SD p-value
Genetic distances
LTR 0.1345 0.035 0.157 0.036 0.0085c
Protease 0.0664 0.0189 0.071 0.0179 0.0085c
Envelope 0.1805 0.046 0.2 0.037 0.0001c
Envelope
Synonymous substitutions 0.2204 0.0583 0.2431 0.07264 0.0022c
Nonsynonymous substitutions 0.115 0.02651 0.1236 0.02295 0.0001c
Ratio ds/dn 1.979 0.589 2.047 0.7758 0.6855
Protease
Synonymous substitutions 0.1551 0.0431 0.1703 0.04397 0.0001c
Nonsynonymous substitutions 0.02826 0.01171 0.0297 0.0116 0.2202
Ratio ds/dn 6.123 7.521 7.196 5.265 0.3129
a1999 samples: LTR (n  21), env (n  18), and pr (n  20).
b2004 samples: LTR (n  37), env (n  32), and pr (n  31).
cp-values 0.05 were considered statistically significant.
TABLE 2. FREQUENCY OF KNOWN
MUTATIONS/POLYMORPHISMS DETECTED IN
HIV PROTEASE FROM ARV DRUG-NAIVE WOMEN
Protease
Number of Frequency of mutation (%)















onymous and nonsynonymous substitutions may therefore pro-
vide information on the degree of selection operating on the
virus. Both in env and pr, the number of synonymous substi-
tutions increased between 1999 and 2004. Nonsynonymous
substitutions also increased in env, indicating that higher vari-
ability in this region of env may be caused by the evolutionary
force of genetic drift in addition to external selective pressure.
An interesting finding of the present study is the higher syn-
onymous and nonsynonymous diversity found within the 2004
sequences as compared to the 1999 sequences. Moreover, me-
dian genetic distances were also higher for the 2004 sequences.
Although we cannot exclude that differences observed are due
to small sample size, it can be hypothesized that the higher het-
erogeneity of the 2004 viruses may be due to both (1) the in-
troduction of new viruses in Mozambique between 1999 and
2004 as well as (2) the diversification of the viruses introduced
prior to 1999. Whether this diversification affects the trans-
missibility or virulence of subtype C viruses remains to be elu-
cidated. It has been suggested that the genetic bottlenecks cre-
ated by the transmission of few clones of HIV-1 and pressure
from the immune system could reduce the overall fitness of the
virus. Furthermore, with the dramatic global spread of subtype
C, the question has been raised as to whether this dominance
is related to an attenuation of virulence, but this has yet to be
investigated.36
Primary resistance mutations to protease inhibitors were
not found in either the 1999 or 2004 sequences. Neverthe-
less, a high prevalence of secondary resistance mutations was
observed in our sequences, predominantly the M36I and I93L
mutations. Although the prevalence of polymorphisms is
higher than that described for subtype B viruses, these results
are consistent with the high prevalence described in two stud-
ies conducted in Mozambique and with other studies per-
formed on non-B clades.10,14,15,37,38 The implications of a
high prevalence of secondary resistance mutations in subtype
C are not known, although the mutation at M36 in the B clade
has been associated with greater risk of virological failure
and with the appearance of the major resistance mutation
L90M.12,39
The prediction of CCR5 or CXCR4 receptor usage based on
the net charge of the V3 loop and the presence of the GPGQ
crown indicated that most viruses in this study potentially used
CCR5, with 13% potentially displaying X4 or mixed R5X4 us-
age. Little is known in Africa regarding CCR5 and CXCR4 us-
age as a reflection of disease progression. It is generally ac-
cepted that viruses present in an individual early in HIV-1
infection are predominantly R5, but the timing of the R5-X4
switch for subtype C viruses is unclear.40–43 Nevertheless, as
described by Coetzer et al., our results show that CXCR4 us-
age is not a rare event in subtype C viruses as previously sug-
gested.44–46 Unfortunately, CD4 T cell counts were not avail-
able for the samples analyzed and consequently we were unable
to assess correlations between CXCR4 usage and disease stage.
In conclusion, this study describes the genetic diversity, mo-
lecular evolution, and epidemiological patterns of HIV-1 spread
in women from a rural area of southern Mozambique. As im-
plementation of HAART has begun in this area, the description
of drug resistance polymorphisms in antiretroviral drug-naive
women will be relevant to future evaluations of antiretroviral
therapy programs.
SEQUENCE DATA
The GenBank accession numbers of the sequences reported
in this paper are EF407648–EF407665 and EF407667–
EF407809. The GenBank accession numbers of the reference
sequences from neighboring countries used in the phylogenetic
trees are AF023427, AF023431, AF127568, AF023430,
AF096778, AF096780, AF096782, U63536, U63539,
AY452654, AF196734, AF196733, AF196732, AY452658,
AY162225, AF290029, AY162224, AF239628, AF239638,
AF239633, AF239654, AF254734, AF254686, AF254723,
AF254711, AB192571, AF102218, AF102202, AF102207,
AB191674, AB191676, AB191660, AB191679, U08455,
U51292, AM076841, AM076843, AM076847, and AM076846.
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